DEVELOPMENT AND OPTIMIZATION OF COATED TABLET CONTAINING AMLODIPINE AND VALSARTAN FOR HYPERTENSION TREATMENT
DOI:
https://doi.org/10.22159/ijap.2024v16i4.50984Keywords:
Amlodipine, Valsartan, Film-coated tablets, In vitro equivalence, HypertensionAbstract
Objective: To develop and optimize the formulation of coated tablets containing these Active Pharmaceutical Ingredients (APIs) with in vitro equivalence to that of the original drug.
Methods: Design Expert and BCPharSoft OPT softwares were applied in the development and optimization of film-coated tablets of amlodipine 5 mg and valsartan 80 mg, in order to obtain a tablet formulation with in vitro equivalence to the original drug in three dissolution testing environments. Evaluating through appearance, identification, medium hardness, weight uniformity, in vitro equivalence, assay.
Results: An optimized formulation of film-coated tablets with in vitro equivalence to the referent drug was obtained. For the tablet core, it is composed of amlodipine besylate 6.94 mg (equivalent to 5 mg amlodipine) and valsartan 80 mg with excipients of 9.77% crospovidone XL, 2% aerosil, 2.75% magnesium stearate, 42.01% avicel PH 112, with a hardness of 70-90 N. The film-coating suspension comprises 4.75% Hydroxypropyl Methylcellulose 6cps (HPMC 6cps), 0.42% polyethylene glycol 6000 (PEG 6000), 0.84% talc, 1.77% titanium dioxide (TiO2), 0.12% yellow iron oxide, in 92.1% ethanol 96%-water (2:1).
Conclusion: In the current study, a film-coated tablet formulation with in vitro equivalence of two APIs to the original drug in all three environments was successfully developed and optimized. The obtained results are an important premise for the development of related generic drugs in the pharmaceutical market of developing countries, which not only reduces the product price but also help less wealthy patients in developing countries to better control hypertension disease.
Downloads
References
Ramteke M, Kasture A. Simultaneous UV-spectrophotometric method for the estimation of atenolol and amlodipine besylate in combined dosage form. Indian J Pharm Sci. 2006;68(3):394. doi: 10.4103/0250-474X.26665.
Campbell NR, Paccot Burnens M, Whelton PK, Angell SY, Jaffe MG, Cohn J. World Health Organization guideline on pharmacological treatment of hypertension: policy implications for the region of the Americas. Lancet Reg Health Am 2022;9. doi: 10.1016/j.lana.2022.100219.
Haque SM, Alsawalha M. Analytical methods for the quantitation of amlodipine besylate AND atorvastatin calcium in pharmaceutical dosage form AND biological fluids. Int J App Pharm. 2019;11(3):5-15. doi: 10.22159/ijap.2019v11i3.32566.
Elliott WJ, Ram CV. Calcium channel blockers: calcium channel blockers. J Clin Hypertens. 2011;13(9):687-9. doi: 10.1111/j.1751-7176.2011.00513.x.
Jin J, Cao F, Ping QN, Zhang C. Preparation and dissolution of compound valsartan and amlodipine besylate tablets. Chin J New Drugs. 2012;21:1806-11.
Ghobashy MM, Alshangiti DM, Alkhursani SA, Al-Gahtany SA, Shokr FS, Madani M. Improvement of in vitro dissolution of the poor water-soluble amlodipine drug by solid dispersion with irradiated polyvinylpyrrolidone. ACS Omega. 2020;5(34):21476-87. doi: 10.1021/acsomega.0c01910, PMID 32905418.
Huynh DT, Tran VHT, Huynh VH, Pham DT. Floating tablets incorporating curcumin solid dispersion as a potential pharmaceutical dosage form for stomach cancer treatment. J App Pharm Sci. 2023;13(4):240-50. doi: 10.7324/JAPS.2023.114417.
Huynh DT, Hai HT, Hau NM, Lan HK, Vinh TP, Tran VD. Preparations and characterizations of effervescent granules containing azithromycin solid dispersion for children and elder: solubility enhancement, taste-masking, and digestive acidic protection. Heliyon Heliyon. 2023;9(6):e16592. doi: 10.1016/j.heliyon.2023.e16592, PMID 37292293.
United States of America Pharmacopeial Convention the United States of America Pharmacopeia; Rockville; 2020.
Costa P. An alternative method to the evaluation of similarity factor in dissolution testing. Int J Pharm. 2001;220(1-2):77-83. doi: 10.1016/S0378-5173(01)00651-2, PMID 11376969.
Abdoh A, Al‐Omari MM, Badwan AA, Jaber AM. Amlodipine besylate–excipients interaction in solid dosage form. Pharm Dev Technol. 2004;9(1):15-24. doi: 10.1081/PDT-120027414, PMID 15000463.
Badwar MR, Borse SL, Junagade MS, Jadhav AG. Formulation and evaluation of mouth-dissolving tablet of amlodipine besylate. Int J App Pharm. 2019;11(4):132-9. doi: 10.22159/ijap.2019v11i4.31288.
Merwe Van Der J, Steenekamp J, Steyn D, Hamman J. The role of functional excipients in solid oral dosage forms to overcome poor drug dissolution and bioavailability. Pharmaceutics. 2020;12(5):393. doi: 10.3390/pharmaceutics12050393, PMID 32344802.
Behin. Formulation and characterization of fast disintegrating tablets of amlodipine using super-disintegrants. J App Pharm Sci. 2012;2(8):118-23. doi: 10.7324/JAPS.2012.2819.
Ramirez DG, Robles LV. Contrasting the crospovidones functionality as excipients for direct compression. Braz J Pharm Sci. 2015;51(1):155-71. doi: 10.1590/S1984-82502015000100016.
Park C, Lee JH, Jin G, Ngo HV, Park JB, Tran TT. Release kinetics of hydroxypropyl methylcellulose governing drug release and hydrodynamic changes of matrix tablet. Curr Drug Deliv. 2022;19(5):520-33. doi: 10.2174/1567201818666210820101549, PMID 34420504.
Published
How to Cite
Issue
Section
Copyright (c) 2024 DUYEN THI MY HUYNH, TRUONG PHU VINH, TRAN DUNG TAM, MINH-NGOC T. LE, PHUOC-VINH NGUYEN
This work is licensed under a Creative Commons Attribution 4.0 International License.
